Healthcare · Biotechnology
Price
$14.22
Market Cap
$23.0M
Employees
6
Beta
2.18
Avg Volume
229,217
CEO
John Friend
Business Description
Kazia Therapeutics Limited, together with its subsidiaries, operates as an oncology-focused biotechnology company in Israel. The company's lead development candidate is paxalisib, a small molecule, brain-penetrant inhibitor of the phosphoinositide-3-kinase (PI3K)/AKT/mammalian target of rapamycin (mTOR) pathway, which is in Phase II/III clinical trial for the treatment of glioblastoma; in Phase II trial to treat isocitrate dehydrogenase-mutant glioma, primary central nervous system (CNS) lymphoma, diffuse intrinsic pontine glioma, and brain metastases; and in pre-clinical studies to treat triple-negative breast cancer, as well as for the treatment of atypical rhabdoid/teratoid tumors. It also develops EVT801, a small-molecule selective inhibitor of vascular endothelial growth factor receptor 3 that is in Phase I clinical trial to treat advanced solid tumors and ovarian cancer. The company has collaborations with the Australian and New Zealand Children’s Haematology/Oncology Group, Genentech Inc., Global Coalition for Adaptive Research, Vivesto AB, Simcere Pharmaceutical Group Ltd, Evotec SE, Sovargen Co., Ltd, and QIMR Berghofer Medical Research Institute. Kazia Therapeutics Limited was formerly known as Novogen Limited and changed its name to Kazia Therapeutics Limited in November 2017. Kazia Therapeutics Limited was incorporated in 1994 and is based in Sydney, Australia.
Business History
Price History (1 Year)
Revenue & Net Income Trend
The directional story — useful even when net income is negative.
Revenue
The top line — total sales before any costs or taxes are subtracted. A measure of how much business the company is doing.
Net Income
The bottom line — profit left after subtracting all expenses, interest, and taxes from revenue. Reflects accounting profitability, but includes non-cash items like depreciation, so it isn't the same as cash earned.
Operating Cash Flow
The real cash generated by the day-to-day business — selling products, paying suppliers, collecting from customers. Calculated from net income by adding back non-cash items and adjusting for timing (unpaid bills, unsold inventory). When OCF consistently lags net income, the reported profit may not be converting to real money.
| Period | Revenue | Net Income | Net Margin | YoY/QoQ |
|---|
Key Metrics
API Direct from provider
CALC Derived from statements
P/E Ratio (Price per dollar of earnings)
CALCStock Price / EPS (Diluted)
-0.75
Stock Price: $14.22
EPS (Diluted): -18.90
EPS (Diluted): -18.90
P/B Ratio (Price vs net asset value)
APIStock Price / Book Value Per Share
-1.26
Stock Price: $14.22
Total Equity: -$8.30M
Shares: 1,095,343
Total Equity: -$8.30M
Shares: 1,095,343
EV/EBITDA (Total value vs operating profit)
APIEnterprise Value / EBITDA
-0.49
Market Cap: $23.03M
Total Debt: $396,000
Cash: $4.35M
EBITDA: -$13.28M
Total Debt: $396,000
Cash: $4.35M
EBITDA: -$13.28M
Enterprise Value (Takeover price (cap + debt - cash))
APIMarket Cap + Total Debt - Cash
$6.5M
Market Cap: $23.03M
Total Debt: $396,000
Cash: $4.35M
Total Debt: $396,000
Cash: $4.35M
P/S Ratio (Price per dollar of revenue)
APIStock Price / Revenue Per Share
248.45
Stock Price: $14.22
Revenue: $42,000
Shares: 1,095,343
Revenue: $42,000
Shares: 1,095,343
EV/Sales (Total value vs revenue — works when P/E can't)
API154.43
Gross Margin (Revenue left after direct costs)
APIGross Profit / Revenue
100.0%
Gross Profit: $42,000
Revenue: $42,000
Revenue: $42,000
Operating Margin (Revenue left after all operations)
APIOperating Income / Revenue
-33,850.0%
Operating Income: -$14.22M
Revenue: $42,000
Revenue: $42,000
Net Margin (Revenue left as actual profit)
APINet Income / Revenue
-49,290.5%
Net Income: -$20.70M
Revenue: $42,000
Revenue: $42,000
ROE (Profit from shareholder equity)
CALCNet Income / Total Equity
249.4%
Net Income: -$20.70M
Total Equity: -$8.30M
Total Equity: -$8.30M
ROIC (Profit from all invested capital)
CALCNOPAT / Invested Capital
107.0%
Operating Income: -$14.22M
Tax Rate: 7.8%
Equity: -$8.30M
Total Debt: $396,000
Cash: $4.35M
Tax Rate: 7.8%
Equity: -$8.30M
Total Debt: $396,000
Cash: $4.35M
Current Ratio (Can it pay short-term bills)
APICurrent Assets / Current Liabilities
0.35
Current Assets: $4.93M
Current Liabilities: $14.05M
Current Liabilities: $14.05M
Debt/Equity (Leverage — debt vs equity)
CALCTotal Debt / Total Equity
-0.05
Short-Term Debt: $396,000
Long-Term Debt: $0.00
Total Debt: $396,000
Total Equity: -$8.30M
Long-Term Debt: $0.00
Total Debt: $396,000
Total Equity: -$8.30M
Rev/Share (Top-line per share)
CALCRevenue / Shares Outstanding
$0.04
Revenue: $42,000
Shares: 1,095,343
Shares: 1,095,343
Book Value/Share (Net assets per share)
CALC(Total Assets - Total Liabilities) / Shares
$-7.58
Total Equity: -$8.30M
Shares: 1,095,343
Shares: 1,095,343
FCF/Share (Real cash generated per share)
CALC(Operating Cash Flow + CapEx) / Shares
$-12.12
Operating CF: -$13.28M
CapEx: $0.00
Shares: 1,095,343
CapEx: $0.00
Shares: 1,095,343
Div Yield (Annual income from holding)
APILast Annual Dividend / Stock Price
0.0%
Last Dividend: N/A
Stock Price: $14.22
Stock Price: $14.22
Payout Ratio (Earnings paid out as dividends)
Dividends Paid / Net Income
—
Dividends Paid: N/A
Net Income: -$20.70M
Net Income: -$20.70M
Dividends paid not available in cash flow statement
Industry Benchmarks
Compares KZIA against LLM-researched typical ranges for its
industry. One research call per industry, cached indefinitely — every stock in the same industry
reuses the same baseline.
Deep Analysis
Pre-flight intelligence scans the company first, then routes to the right analytical methods.
0
Company Classification
— What type of company is this?
1
Industry Landscape
— Where is the industry headed?
2
Company Momentum
— Where is this company trending?
3
Forward Projection
— 1Y & 2Y projected metrics (requires Layer 1 + 2)
4a
DCF Valuation
— Present value of future cash flows
4b
Earnings Power Value
— Floor value — worth with zero growth
4c
Anchored PE
— Industry PE adjusted for growth differential
4d
Reverse DCF
— What growth is the market pricing in?
4e
Revenue-Based DCF
— For growth/narrative companies (skip if mature earner)
4f
Anchored P/S
— Price-to-Sales peer comparison (skip if mature earner)
4g
Scenario Analysis
— Bull / Base / Bear (skip if mature earner)
4h
Dividend Discount Model
— For dividend/income stocks only
4i
Book Value Analysis
— For deep value / turnaround stocks only
4j
Insider Activity
— Are insiders buying or selling?
4f
Cash Flow Quality
— How trustworthy is the FCF?
4g
Debt Maturity Risk
— Can it handle its debt?
4h
Macro Environment
— Rates, market valuation, volatility
4i
Sector Intelligence
— How does this company compare within its sector?
4j
Revenue Confidence
— How reliable is the growth projection?
4k
Sensitivity Analysis
— How fragile is the fair value estimate?
4l
Sector Demand Cycle
— Is the sector in a boom, steady state, or contraction?
5
AI Investigation
— Adaptive research engine (Claude)
5b
Thesis Evaluation
— What does the market believe? (narrative/platform stocks only)
6
Valuation Synthesis
— Weighted verdict from all methods (requires Layer 4)
Income Statement (Annual)
Last updated: Jun 20, 2026 10:32am (6d ago)| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | $15.2M | $10,000 | $555 | $2.3M | $42,000 |
| Cost of Revenue | $0 | $0 | $0 | $0 | $0 |
| Gross Profit | $15.2M | $10,000 | $555 | $2.3M | $42,000 |
| Operating Expenses | $21.6M | $25.4M | $24.1M | $30.8M | $14.3M |
| Operating Income | -$6.4M | -$25.4M | -$24.1M | -$28.5M | -$14.2M |
| Net Income | -$8.4M | -$25.0M | -$20.5M | -$26.8M | -$20.7M |
| EBITDA | -$5.1M | -$23.5M | -$22.3M | -$26.6M | -$13.3M |
| EPS | $-35.80 | $-95.00 | $-55.00 | $-55.00 | $-18.90 |
| EPS (Diluted) | — | — | — | — | — |
Balance Sheet (Annual)
Last updated: Jun 20, 2026 10:32am (6d ago)| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | $27.6M | $7.4M | $5.2M | $1.7M | $4.3M |
| Total Current Assets | $29.4M | $9.4M | $10.8M | $6.1M | $4.9M |
| Total Assets | $58.1M | $35.9M | $28.1M | $21.6M | $6.1M |
| Current Liabilities | $8.3M | $6.7M | $7.6M | $25.8M | $14.1M |
| Long-Term Debt | $0 | $0 | $0 | $0 | $0 |
| Total Liabilities | $20.2M | $17.6M | $16.0M | $31.6M | $14.4M |
| Total Equity | $37.9M | $18.3M | $12.1M | -$10.0M | -$8.3M |
| Retained Earnings | -$44.2M | -$68.6M | -$89.1M | -$115.1M | -$134.8M |
Cash Flow (Annual)
Last updated: Jun 20, 2026 10:32am (6d ago)| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Operating Cash Flow | -$9.1M | -$22.8M | -$15.2M | -$9.6M | -$13.3M |
| Capital Expenditure | $0 | $0 | $0 | $0 | $0 |
| Free Cash Flow | -$9.1M | -$22.8M | -$15.2M | -$9.6M | -$13.3M |
| Acquisitions (net) | $0 | -$2.4M | $0 | $0 | $0 |
| Debt Repayment | — | — | — | — | — |
| Dividends Paid | — | — | — | — | — |
| Stock Buybacks | $0 | $0 | $0 | $0 | $0 |
| Net Change in Cash | $18.8M | -$20.2M | -$2.1M | -$3.6M | $2.7M |
Analyst Estimates (Annual)
Last updated: Jun 27, 2026 12:06am (8h ago)| Metric | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|
| Revenue |
$145,000 $106,949 – $183,050
|
$5.1M $3.8M – $6.4M
|
$43.0M $31.7M – $54.3M
|
$139.5M $102.9M – $176.2M
|
| EBITDA |
$-125,762 $-158,763 – $-92,759
|
-$4.4M -$5.6M – -$3.3M
|
-$37.3M -$47.1M – -$27.5M
|
-$121.0M -$152.8M – -$89.3M
|
| Net Income |
-$1.7M -$2.2M – -$1.1M
|
-$2.2M -$2.9M – -$1.4M
|
$185,956 $122,514 – $249,398
|
$4.7M $3.1M – $6.3M
|
| EPS | — | — | — | — |
Growth Trends (YoY %)
Last updated: Jun 20, 2026 10:32am (6d ago)| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Revenue Growth | -99.9% | -94.5% | +415,755.9% | -98.2% |
| Gross Profit Growth | -99.9% | -94.5% | +415,755.9% | -98.2% |
| Operating Income Growth | -298.4% | +5.0% | -18.0% | +50.0% |
| Net Income Growth | -197.1% | +18.2% | -30.8% | +22.7% |
| EBITDA Growth | -360.1% | +5.3% | -19.4% | +50.1% |
Narrative Economics
The story the market is telling about this stock — the intangible X-factor
(founder mythology, cult dynamics, TAM-of-imagination) that moves price beyond
what cash flows alone explain. After Shiller, Narrative Economics.
No narrative profile yet for KZIA — it's generated by the pipeline (
market-narrative step).
No community reviews yet for KZIA.
Be the first — hit How to Contribute, have any AI review this page, and paste its take back here.
My Notes
personal — only you see this
Sign in to save personal notes and rate your interest in this stock.
Data via Financial Modeling Prep · Cached for performance · fmp
v1.1.352 · d1100787 · 2026-06-26 11:39:30